Keros Pharma - KROS Short-Term Debt to Capital

Historical price action for Keros Therapeutics (KROS) shows the metric value at 0.01. Sanctions restrictions impacting the business are blocking the cross-border exchange of biomaterials and scientific research. Keros Therapeutics (KROS) employs an asset-light strategy, outsourcing the production of blood pathology drugs to external contractors. Currently, innovative muscle therapy agents are undergoing testing in preparation for market entry and full-scale commercial sales.

For the biotech company Keros Therapeutics (KROS), which faces high R&D expenditures, managing short-term liabilities is critical for maintaining liquidity until clinical trials are completed. This metric is calculated as the ratio of loans maturing within one year to equity, determining the business's dependence on rapid external financing. The trend of short-term loans to equity confirms the resilience of the issuer's balance sheet in the face of operating losses.